Need help finding what you are looking for?
Contact Us
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355795
PUBLISHER: FirstWord Group | PRODUCT CODE: 1355795
Non-Small Cell Lung Cancer - Immunotherapies - KOL Insight
PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
How do KOLs interpret data from Checkmate-816, and how does this now inform the treatment of patients with early-stage resectable NSCLC without EGFR or ALK genomic alterations? Why do oncologists say the KEYNOTE-671 findings for Merck & Co.'s Keytruda will likely impact NSCLC treatment practice? How do experts assess the potential to re-challenge with IO-based therapy? KOLs critically assess the prospects of launched and pipeline therapies.
In addition to the full report, licensed users have access to KOL Bulletins via the Attachments area.
Table of Contents
Executive summary (9)
Current and future treatment algorithm
Research objectives (2)
PD-1/L1 and CTLA-4-based regimens (40)
- Approved/pipeline programmes (40)
- Advanced NSCLC (Merck & Co.; BMS; Roche; AstraZeneca; Regeneron; Daiichi Sankyo) (11)
- Stage III non-resectable NSCLC (Merck & Co.; BMS; AstraZeneca) (6)
- Early-stage NSCLC (Merck & Co.; BMS; Roche; AstraZeneca) (13)
- Post-ICI settings (10)
Anti-PD1/VEGF bispecific antibody (7)
- Pipeline therapy (7)
- Ivonescimab (SMT112; Summit) (7)
Anti-TIGIT monoclonal antibodies (10)
- Pipeline therapies (10)
- Tiragolumab (RG6058; Roche), vibostolimab (MK-7684; Merck & Co.), ociperlimab (BGB-A1217; BeiGene) and domvanalimab (AB154; Arcus/Gilead) (10)
LAG3 agents (5)
- Pipeline therapies (5)
- Eftilagimod alpha (IMP321; Immutep) (5)
Future treatment trends (7)
- Key insights summary (7)
Appendix (6)
- KOL details (6)
- KOLs from the USA (2)
- KOLs from Europe (3)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.